Patents Assigned to Replicate Bioscience, Inc.
  • Compositions and methods for expression of IL-12 and IL-1RA
    Patent number: 11873507
    Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: January 16, 2024
    Assignee: Replicate Bioscience, Inc.
    Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad
  • Compositions and methods for the prevention and treatment of rabies virus infection
    Patent number: 11730804
    Abstract: The present disclosure relates generally to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating rabies virus infection.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: August 22, 2023
    Assignee: Replicate Bioscience, Inc.
    Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad, Andrew Geall
  • Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
    Patent number: 11510975
    Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified equine encephalitis virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating cancer.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: November 29, 2022
    Assignee: Replicate Bioscience, Inc.
    Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad